Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 15/20 | 0.75 |
| ▸ | IMPDH1 | P20839 | 6/20 | 0.69 |
| ▸ | AAK1 | Q2M2I8 | 6/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6483749 | 0.92 | IMPDH2 (0.74) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL6501653 | 0.92 | IMPDH2 (0.70) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL6486074 | 0.92 | IMPDH2 (0.73) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL6488624 | 0.92 | IMPDH2 (0.70) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL6485618 | 0.88 | IMPDH2 (0.63) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL6500037 | 0.87 | IMPDH2 (0.79) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL1473286 | 0.86 | IMPDH2 (1.00) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL6486279 | 0.85 | IMPDH2 (0.77) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL1474188 | 0.84 | IMPDH2 (0.85) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL6485875 | 0.84 | IMPDH2 (0.69) | IMPDH2IMPDH1AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6867299-B2 | Inosine monophosphate dehydrogenase (IMPDH); use as immunosuppressants, anticancer agents and antiviral agents | HOFFMANN-LA ROCHE INC. (US) | 2005-03-15 | — | — | US | claimed |
| US-6932961-B1 | Oxazinocarbazoles for the treatment of CNS diseases | PHARMACIA & UPJOHN COMPANY (US) | 2005-08-23 | — | — | US | disclosed |
| US-6867299-B2 | Inosine monophosphate dehydrogenase (IMPDH); use as immunosuppressants, anticancer agents and antiviral agents | HOFFMANN-LA ROCHE INC. (US) | 2005-03-15 | — | — | US | disclosed |
| US-6821970-B2 | USEFUL FOR TREATING DISEASES WHEREIN MODULATION OF 5-HT ACTIVITY IS DESIRED; NERVOUS SYSTEM DISORDERS | PHARMACIA & UPJOHN COMPANY | 2004-11-23 | — | — | US | disclosed |
| EP-1200447-B1 | OXAZINOCARBAZOLES FOR THE TREATMENT OF CNS DISEASES | UPJOHN CO (US) | 2003-10-01 | — | — | EP | disclosed |
| US-20020169317-A1 | Oxazinocarbazoles for the treatment of CNS diseases | TENBRINK RUTH ELIZABETH (US) | 2002-11-14 | — | — | US | disclosed |
| US-6448397-B1 | TREATING CENTRAL NERVOUS SYSTEM DISEASES WITH MODULATION OF 5-HT ACTIVITY; ADRENERGIC, DOPAMINERGIC, AND SEROTONERGIC NEUROTRANSMITTERS; PSYCHOSIS, PARAPHRENIA, DEPRESSION, MANIA, SCHIZOPHRENIA, ANXIETY, MIGRAINE HEADACHE, DRUG ADDICTION | PHARMACIA & UPJOHN COMPANY | 2002-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169317-A1 | Oxazinocarbazoles for the treatment of CNS diseases | HTR1B, TPH1, HTR7 | IMPDH2 1898/4885IMPDH1 1265/4885AAK1 3347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.